Žilvinas Dambrauskas

Circulating cell-free DNA fragmentomics distinguishes pancreatic ductal adenocarcinoma from non-malignant conditions

Romualdas Riauka, Darius Stukas, Arenida Bartkevičienė, Inga Žievytė et autres

Pancreatic ductal adenocarcinoma (PDAC) has poor survival rates due to late diagnosis and limited early detection methods. Existing serum biomarkers have inadequate sensitivity and specificity. This study assessed whether circulating cell-free DNA (cfDNA) fragmentomic features could distinguish PDAC from chronic pancreatitis (CP) …

lt (code pays fourni par la source)

Proteomic Differentiation of Colorectal Cancer From Normal Tissue via Ex Vivo E‐Biopsy: A Novel Approach to Molecular Sampling for Diagnostic Precision

Gintautas Saulis, Edward Vitkin, Rita Saulė, Julia Wise et autres

Colorectal cancer (CRC) is one of the most common malignancies worldwide. Early and accurate diagnosis remains a clinical priority, yet current biopsy techniques are invasive, spatially limited, and may not capture the molecular heterogeneity of tumors. We evaluated the feasibility and diagnostic …

lt, il, fr, us (code pays fourni par la source)

Circulating Cell-Free DNA fragmentomics distinguishes pancreatic ductal adenocarcinoma from non- malignant conditions

Romualdas Riauka, Darius Stukas, Arenida Bartkevičienė, Inga Žievytė et autres

lt (code pays fourni par la source)

Periferinio kraujo vienbranduolių ląstelių pokyčiai po chirurginio gydymo sergant kiaušidžių vėžiu

Jonas Ulevičius, Aldona Jasukaitienė, Žilvinas Dambrauskas, Antanas Gulbinas et autres

Kiaušidžių vėžys (KV) yra aštunta pagal dažnumą moterų onkologinė liga pasaulyje, dažniausiai diagnozuojama pažengusiose stadijose, todėl gydymo rezultatai yra prasti - bendrasis 5 metų išgyvenamumas siekia tik apie 49 proc. Citoredukcinė operacija išlieka pagrindiniu gydymo būdu, tačiau chirurginės traumos sukeliami imuninės sistemos …

de, lt (code pays fourni par la source)

Overexpression of EMT-related transcription factors SNAI1 and ZEB1 is associated with more aggressive clinicopathological features of pancreatic cancer

Kęstutis Urbonas, Gabija Stachneviciute, Aldona Jasukaitienė, Povilas Ignatavicius et autres

BACKGROUND/OBJECTIVES: Pancreatic ductal adenocarcinoma (PDAC) is one of the most fatal malignancies due to its aggressive nature and resistance to therapy. The epithelial-mesenchymal transition (EMT) drives cancer progression, regulated by transcription factors (TFs) such as SNAI1, SNAI2, ZEB1, ZEB2, and TWIST. This …

lt (code pays fourni par la source)

Baseline AHR expression shapes immune response to pharmacological modulation in PBMCs from pancreatic cancer patients

Arenida Bartkevičienė, Aldona Jasukaitienė, Inga Žievytė, Sandra Ivanauskienė et autres

Background: Pancreatic ductal adenocarcinoma (PDAC) remains largely unresponsive to immunotherapy because of its highly immunosuppressive tumor microenvironment. Aryl hydrocarbon receptor (AHR), a ligand-dependent transcription factor, has emerged as a key regulator of immune homeostasis and inflammation. However, its systemic immunomodulatory role in …

lt, ee, lv, no, ca (code pays fourni par la source)

Targeting AHR decreases PDAC cell migration and invasiveness in 2D and 3D systems, in vitro

Darius Stukas, Gabrielė Karvelytė, Gabija Stachneviciute, Inga Žievytė et autres

lt (code pays fourni par la source)

Regulatory Role of ELAVL1 in EMT-Driven Pancreatic Cancer Progression

Gabija Stachnevičiūtė, Darius Stukas, Kęstutis Urbonas, Gabrielė Karvelytė et autres

lt (code pays fourni par la source)

Aryl Hydrocarbon Receptor Modulation Alters Immune Checkpoint Expression and Inflammatory Mediators in Pancreatic Ductal Adenocarcinoma

Arenida Bartkevičienė, Kornelija Jenceviciute, Inga Žievytė, Gabija Stachneviciute et autres

lt (code pays fourni par la source)

Loss of aryl hydrocarbon receptor reduces pancreatic tumor growth by increasing immune cell infiltration

Vinicius Kannen, Ninni Elise Olafsen, Siddhartha Das, Paolo Giuliana et autres

Pancreatic ductal adenocarcinoma (PDAC) is a devastating disease which remains poorly understood. Increasing evidence suggests that the aryl hydrocarbon receptor (AHR) plays a role in the pathogenesis of several cancers; however, its role in PDAC is unclear because AHR exhibits both pro- …

ca, no, it, ee, lv, lt (code pays fourni par la source)

Small-molecule inhibitor BAY synergizes with gemcitabine through AHR inhibition in pancreatic cancer cells

Darius Stukas, Inga Žievytė, Sandra Ivanauskienė, Gabrielė Karvelytė et autres

Pancreatic cancer (PC) presents a significant challenge in treatment efficacy due to late-stage diagnosis and chemoresistance. The effects of the combination of a selective small-molecule AHR inhibitor and gemcitabine treatmenteffectiveness in PC cells has been a focus of research. This study utilized …

lt, no, ee, lv (code pays fourni par la source)

Loss of Parp7 increases type I interferon signalling and reduces pancreatic tumour growth by enhancing immune cell infiltration

Vinicius Kannen, Marit Rasmussen, Siddhartha Das, Paolo Giuliana et autres

Background: Pancreatic ductal adenocarcinoma (PDAC) is one of the most lethal forms of cancer, and despite low incidence rates, it remains the sixth leading cause of cancer related deaths worldwide. Immunotherapy, which aims to enhance the immune system's ability to recognize and …

ca, no, it, ee, lv, lt (code pays fourni par la source)